Korean J Schizophr Res.  2014 Oct;17(2):72-79. 10.16946/kjsr.2014.17.2.72.

Correlation of Lifetime Symptom Dimensions with Cognitive Function and Other Clinical Characteristics in Schizophrenia Patients

• Cho Y
• Ryu S
• Oh H
• Oh S
• Park T
• Yoon SC
• Hong KS

• KMID: 2288290
• DOI: http://doi.org/10.16946/kjsr.2014.17.2.72

Abstract

OBJECTIVES
Considering large diversity of clinical presentation of schizophrenia, it is important to identify valid clinical subtypes or dimensions that might have homogeneous biological underpinning. The current study aimed to explore lifetime symptom-based dimensional phenotypes in patients with chronic schizophrenia, and to investigate their correlation with cognitive functions and other clinical characteristics.
METHODS
Lifetime-based symptoms and additional clinical variables were measured using the Diagnostic Interview for Genetic Studies and the Schedule for the Deficit Syndrome in 315 clinically stable patients with chronic schizophrenia. Through principal components factor analysis, eight dimensional phenotypes were obtained. Comprehensive neuropsychological tests were administered for 103 out of 315 patients, and domain scores were calculated for cognitive domains defined in the MATRICS consensus battery.
RESULTS
'Non-paranoid delusion factor' including delusions of grandiose or religious nature, showed significant negative correlation with processing speed, working memory, attention/vigilance, and general cognitive ability, and positive correlation with intra-individual variability. 'Negative symptom factor' showed significant negative correlation only with general cognitive ability. Those two factors were also negatively correlated with function levels measured by Global Assessment Scale (GAS), and associated with poor treatment responses.
CONCLUSION
Symptom-based dimensional phenotypes of schizophrenia measured on a lifetime basis showed discriminative correlation with cognitive function domains, global functioning level, and overall treatment responses, indicating their possibility as valid phenotype axes of schizophrenia having homogeneous biologic basis.

Keyword

Schizophrenia; Symptom dimensions; Cognition

MeSH Terms

Appointments and Schedules
Cognition
Consensus
Delusions
Humans
Memory, Short-Term
Neuropsychological Tests
Phenotype
Schizophrenia*

Reference

References

1. Andreasen NC, Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull. 1991; 17:27–49.

2. American Psychiatric Association. Diagnostic And Statistical Manual Of Mental Disorders. 4th ed. (Text Revision).Washington, DC: American Psychiatric Press;2000.

3. American Psychiatric Association. Diagnostic And Statistical Manual of Mental Disorders. 5th ed.Washington, DC: American Psychiatric Press;2013.

4. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013; 150:3–10.

5. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102:1–18.

6. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK. Symptomatic and neuropsychological components of defect states. Schizophr Bull. 1985; 11:409–419.

7. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987; 151:145–151.

8. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995; 52:341–351.

9. Peralta V, de Leon J, Cuesta MJ. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry. 1992; 161:335–343.

10. Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O'Neill FA, et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry. 2005; 162:1824–1832.

11. Rietkerk T, Boks MP, Sommer IE, Liddle PF, Ophoff RA, Kahn RS. The genetics of symptom dimensions of schizophrenia: review and metaanalysis. Schizophr Res. 2008; 102:197–205.

12. Vassos E, Sham PC, Cai G, Deng H, Liu X, Sun X, et al. Correlation and familial aggregation of dimensions of psychosis in affected sibling pairs from China. Br J Psychiatry. 2008; 193:305–310.

13. Wickham H, Walsh C, Asherson P, Taylor C, Sigmundson T, Gill M, et al. Familiality of symptom dimensions in schizophrenia. Schizophr Res. 2001; 47:223–232.

14. McGrath JA, Avramopoulos D, Lasseter VK, Wolyniec PS, Fallin MD, Liang KY, et al. Familiality of novel factorial dimensions of schizophrenia. Arch Gen Psychiatry. 2009; 66:591–600.

15. Ryu S, Won HH, Oh S, Kim JW, Park T, Cho EY, et al. Genomewide linkage scan of quantitative traits representing symptom dimensions in multiplex schizophrenia families. Psychiatry Res. 2013; 210:756–760.

16. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000; 14:1–21.

17. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12:426–445.

18. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31:5–19.

19. Bora E, Murray RM. Meta-analysis of Cognitive Deficits in Ultrahigh Risk to Psychosis and First-Episode Psychosis: Do the Cognitive Deficits Progress Over, or After, the Onset of Psychosis? Schizophr Bull. 2014; 40:744–755.

20. Cornblatt BA, Lenzenweger MF, Dworkin RH, Erlenmeyer-Kimling L. Childhood attentional dysfunctions predict social deficits in unaffected adults at risk for schizophrenia. Br J Psychiatry Suppl. 2006. 59–64.

21. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999; 156:1328–1335.

22. Nopoulos P, Flashman L, Flaum M, Arndt S, Andreasen N. Stability of cognitive functioning early in the course of schizophrenia. Schizophr Res. 1994; 14:29–37.

23. Finkelstein JR, Cannon TD, Gur RE, Gur RC, Moberg P. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol. 1997; 106:203–212.

24. Gur RE, Nimgaonkar VL, Almasy L, Calkins ME, Ragland JD, Pogue-Geile MF, et al. Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. Am J Psychiatry. 2007; 164:813–819.

25. Snitz BE, Macdonald AW 3rd, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006; 32:179–194.

26. Strauss ME. Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull. 1993; 19:215–231.

27. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000; 157:549–559.

28. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry. 1999; 56:749–754.

29. Hughes C, Kumari V, Soni W, Das M, Binneman B, Drozd S, et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res. 2003; 59:137–146.

30. Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry. 1999; 156:1342–1348.

31. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004; 56:301–307.

32. Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004; 72:1–3.

33. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72:29–39.

34. Noh J, Kim JH, Hong KS, Kim N, Nam HJ, Lee D, et al. Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patients. J Korean Med Sci. 2010; 25:276–282.

35. Joo EJ, Joo YH, Hong JP, Hwang S, Maeng SJ, Han JH, et al. Korean version of the diagnostic interview for genetic studies: Validity and reliability. Compr Psychiatry. 2004; 45:225–229.

36. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989; 30:119–123.

37. Guy W. Clinical global impression scale. The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW Publ No ADM 76. 1976; 338:218–222.

38. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976; 33:766–771.

39. Baek JH, Kim JS, Ryu S, Oh S, Noh J, Lee WK, et al. Association of genetic variations in DTNBP1 with cognitive function in schizophrenia patients and healthy subjects. Am J Med Genet B Neuropsychiatr Genet. 2012; 159B:841–849.

40. Holtzer R, Verghese J, Wang C, Hall CB, Lipton RB. Within-person across-neuropsychological test variability and incident dementia. JAMA. 2008; 300:823–830.

41. Carlsson R, Nyman H, Ganse G, Cullberg J. Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis. Acta Psychiatr Scand. 2006; 113:102–111.

42. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocog-nition and functional outcome in schizophrenia: a metaanalysis. Schizophr Res. 2009; 113:189–199.

43. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and metaanalysis of findings to date. Schizophr Bull. 2007; 33:1201–1212.

44. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neu-rocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005; 162:495–506.

45. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012; 137:147–150.

46. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondefi-cit forms of schizophrenia: the concept. Am J Psychiatry. 1988; 145:578–583.

47. Dunayevich E, Keck PE Jr. Prevalence and description of psychotic features in bipolar mania. Curr Psychiatry Rep. 2000; 2:286–290.

48. Arai M, Yamada K, Toyota T, Obata N, Haga S, Yoshida Y, et al. Association between polymorphisms in the promoter region of the sialyltransferase 8B (SIAT8B) gene and schizophrenia. Biol Psychiatry. 2006; 59:652–659.

49. Vazza G, Bertolin C, Scudellaro E, Vettori A, Boaretto F, Rampinelli S, et al. Genomewide scan supports the existence of a susceptibility locus for schizophrenia and bipolar disorder on chromosome 15q26. Mol Psychiatry. 2007; 12:87–93.

50. Taylor MA. Schneiderian first-rank symptoms and clinical prognostic features in schizophrenia. Arch Gen Psychiatry. 1972; 26:64–67.

51. Nordgaard J, Arnfred SM, Handest P, Parnas J. The diagnostic status of first-rank symptoms. Schizophr Bull. 2008; 34:137–154.

52. Lewandowski KE, DePaola J, Camsari GB, Cohen BM, Ongur D. Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singapore. 2009; 38:383–385.

53. Yamada N, Nakajima S, Noguchi T. Age at onset of delusional disorder is dependent on the delusional theme. Acta Psychiatr Scand. 1998; 97:122–124.